Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN
Journal of the American Society of Nephrology · 13.11.2026
DOI: 10.1681/asn.0000001296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 13.11.2026. Verfasst von Carla M Nester und 27 weiteren Autor:innen. Beteiligte Einrichtung: University of Iowa, Stead Family Children's Hospital, Iowa City, Iowa, United States. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis.
Methods
In VALIANT’s 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan ( n =63) or placebo ( n =61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period.
Results
Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, −67.1% [−74.9 to −56.8]; week 52, −67.2% [−75.8 to −55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (–9.6 to 17.9) (26 weeks of placebo), and −53.9% (−64.5 to −40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were −1.2 mL/min/1.73 m 2 (−5.6 to 3.2) (week 26) and –3.7 mL/min/1.73 m 2 (–8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were –7.9 (–11.7 to –4.2) (week 26) and –4.7 (–9.1 to –0.3) (week 52); week-26-to-52 change was +3.0 (–1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan ( n =118) showed proteinuria reduction (geometric mean [95% CI] −63.0% [−69.9 to −54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [−3.8 to 4.0] mL/min/1.73 m 2 ). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred.
Conclusions
Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.
Autor:innen und Institutionen
- University of Iowa, Stead Family Children's Hospital, Iowa City, Iowa, United States.
- Columbia University Irving Medical Center, New York, New York, United States.
- Hospital Vall d'Hebron, Barcelona, Spain.
- Bordeaux University Hospital, Bordeaux, France.
- University of Colorado School of Medicine, Aurora, Colorado.
- University College London, London, United Kingdom.
ORCID-Profile: Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole C A J Van De Kar, Marina Vivarelli, Patrick D Walker, Daniel Zecher, Moglie Le Quintrec, Nabil Melhem, Eli Khankin, Elena Surova, Fadi Fakhouri
Zitieren
APA
Nester, C. M., Bomback, A. S., Ariceta, G., Delmas, Y., Dixon, B. P., Gale, D. P., Greenbaum, L. A., Han, S. H., Isbel, N., Licht, C., Mastrangelo, A., Mizuno, M., Neves de Holanda, M. I., Pickering, M. C., Remuzzi, G., Van De Kar, N. C. A. J., Vivarelli, M., Walker, P. D., Wallace, D., …, & Fakhouri, F. (2026). Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001296
Vancouver
Nester CM, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, et al. Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001296
BibTeX
@article{Nester2026,
author = {Nester, Carla M and Bomback, Andrew S and Ariceta, Gema and Delmas, Yahsou and Dixon, Bradley P and Gale, Daniel P and Greenbaum, Larry A and Han, Seung Hyeok and Isbel, Nicole and Licht, Christoph and Mastrangelo, Antonio and Mizuno, Masashi and Neves de Holanda, Maria Izabel and Pickering, Matthew C and Remuzzi, Giuseppe and Van De Kar, Nicole C A J and Vivarelli, Marina and Walker, Patrick D and Wallace, Dean and Zecher, Daniel and Le Quintrec, Moglie and Borovitz, Yael and Melhem, Nabil and Khankin, Eli and Wang, Zhongshen and Surova, Elena and Szamosi, Johan and Fakhouri, Fadi},
title = {Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN},
journal = {Journal of the American Society of Nephrology},
year = {2026},
doi = {10.1681/asn.0000001296}
}
EUVIMED